Lanean...

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD

BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Med
Egile Nagusiak: Puhan, Milo A., Yu, Tsung, Boyd, Cynthia M., ter Riet, Gerben
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/
https://ncbi.nlm.nih.gov/pubmed/26137986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!